Caribou Biosciences develops cell therapies for blood cancers using gene editing. It last closed at $0.34 on Nov 17, down 3.43% on the day. The average 12-month price target from 2 analysts is $1.00 (+193.5% from the last close), with a high of $1.00 and a low of $1.00.
Only 2 firms rated CRBU in the past 90 days, not enough for a consensus
Average 12-month target
$1.00
▲ 193.5% upside
Based on 2 analysts who set a price target on CRBU in the past 90 days. The average target is $1.00, with a high of $1.00 and a low of $1.00, compared with the last close of $0.34.
Low $1.00Avg $1.00High $1.00
Blue marker: last close $0.34
Highest target$1.00
Average target$1.00
Lowest target$1.00
Latest rating changes
RBC CapitalDowngrade
Oct 7Hold$1
Leerink PartnersDowngrade
Oct 7Hold$1
B of A SecuritiesMaintained
Aug 14Buy$5
Date
Firm
Action
Rating
Price target
Oct 7
RBC Capital
Downgrade
Hold
$1
Oct 7
Leerink Partners
Downgrade
Hold
$1
Aug 14
B of A Securities
Maintained
Buy
$5
Loading…
Technical Analysis
CRBU · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 29% below its 20 day and 130% below its 50 day average. It is 359% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the Pivot at $0.34, and the nearest resistance the Pivot R1 at $0.35.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.3%/day
Key levels
$2.4952 week high+632.4%
$1.56200 day average+358.8%
$1.22100 day average+258.8%
$0.7850 day average+129.4%
$0.58Swing high (Oct 23)+70.6%
$0.4420 day average+29.4%
$0.35Pivot R1+2.9%
$0.34Pivot+0.0%
$0.34Last close
$0.3352 week low−2.9%
$0.33Pivot S1−2.9%
Indicators
RSI (14)
24.94
Oversold below 30
Oversold
MACD
-0.11
Above its signal line
Bullish
Stochastic
4.1
Near the bottom of its range
Oversold
ADX (14)
58.9
Strong downtrend
Williams %R
-91.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-144.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.8%
Change over 10 sessions
Bearish
ATR (14)
$0.05
Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 59.5%/day
Key levels
$2.4952 week high+632.4%
$1.56200 day average+358.8%
$1.22100 day average+258.8%
$0.7850 day average+129.4%
$0.58Swing high (Oct 23)+70.6%
$0.4420 day average+29.4%
$0.35Pivot R1+2.9%
$0.34Pivot+0.0%
$0.34Last close
$0.3352 week low−2.9%
$0.33Pivot S1−2.9%
Indicators
RSI (14)
25.34
Oversold below 30
Oversold
MACD
-0.38
Below its signal line
Bearish
Stochastic
1.6
Near the bottom of its range
Oversold
ADX (14)
28.7
Trending down
Williams %R
-98.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-113.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−73.2%
Change over 10 sessions
Bearish
ATR (14)
$0.20
Typical daily range, 59.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRBU
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CRBU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CRBU usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CRBU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRBU is in one of them and how their past CRBU trades turned out.
Caribou Biosciences is a biopharmaceutical company based in Berkeley, California. It develops cell therapies for cancers of the blood, using a gene editing method built on CRISPR technology. Its lead product candidates are CAR-T cell therapies made from healthy donor cells, and they are in clinical trials for patients with lymphoma or multiple myeloma that has returned or did not respond to earlier treatment.